Victrelis (boceprevir)
From Proteopedia
Contents |
Hepatitis C Virus
The Hepatitis C virus (HCV) is a blood-borne, single stranded RNA virus. [1] Chronic Hepatitis C infection is a leading cause of mortality and morbidity across the globe, affecting almost 170 million people. [2] The genome of HCV encodes a polyprotein precursor of approximately 3,000 amino acids, which are cleaved into 10 proteins by various proteases, one of which is the non-structural protein 3 (NS3) serine protease.[3]
|
Victrelis
Victrelis (boceprevir) is an antiviral Hepatitis C medication approved by the United States Food and Drug Administration in 2011. Victrelis is an inhibitor of the NS3 serine protease.[4] Inhibition of this protease prevents viral replication in Hepatitis C virus infected cells.[4]
Mechanism of Action
Victrelis is a protease inhibitor. A protease is an enzyme that cleaves large polypeptides to create fragments that are small enough to be sequenced for effective replication[5] Victrelis specifically inhibits the HCV NS3/4A protease, which is responsible for cleavage at four different sites along the polyprotein: NS3/NS4A, NS4A/NS4B, NS4B/NS5A, and NS5A/NS5B.[3] In previous experiements, when any member of the catalytic triat was replaced by a different residue, cleavage at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A, and NS5A/NS5B locations was inhibited.[3] Mammals also utilize serine proteases to cleave lengthy polypeptides.[5]
References
- ↑ Centers for Disease Control and Prevention. (2015). Viral hepatitis - hepatitis C information. Retrieved from http://www.cdc.gov/hepatitis/hcv/index.htm
- ↑ doi: https://dx.doi.org/10.1177/1756383X11436317
- ↑ 3.0 3.1 3.2 Lin C. HCV NS3-4A Serine Protease PMID:21250386
- ↑ 4.0 4.1 Merck & Co., Inc. (n.d.) Highlights of prescribing information. Retrieved from https://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf
- ↑ 5.0 5.1 Voet, D., Voet, J., Pratt, C. (2013). Fundamentals of biochemistry: life at the molecular level (4th ed.). Hoboken, New Jersey: John Wiley & Sons, Inc.

